论文部分内容阅读
骨髓增生性疾患(MPD)常有血小板增多特征,可引起血管并发症发生率的增加,对真性红细胞增多症(PV),特发性血小板增多症(ET)无有效疗法。干扰素α-2a和2b对治疗慢性粒细胞白血病(CGL)有效,能导致血液学甚至细胞遗传的缓解,也显示干扰素α-2a对难治的血小板增多患者可使血小板计数正常化,故作者评价重组干扰素α-2a对MPD患者血小板增多的作用。 MPD伴随血小板增多>600×10~9/L为人组标准,采用前瞻性非随机研究。开始每天皮下给干扰素3×10~6U,对治疗无应答在2-4周间期递增至4.5,9和18×10~6U,血小板计数正常化后,逐步减量,以维持血小板计数在正常水平,如发生副作
Myeloproliferative disorders (MPD) are often characterized by thrombocythemia, which can lead to an increased incidence of vascular complications and no effective treatment for polycythemia vera (PV) and idiopathic thrombocythemia (ET). Interferon alpha-2a and 2b are effective in the treatment of chronic myelogenous leukemia (CGL), leading to hematologic or even cytopathic remission, and also show that interferon alpha-2a normalizes platelet count in patients with refractory thrombocytopenia The authors evaluated the effect of recombinant interferon alpha-2a on thrombocytopenia in patients with MPD. MPD with thrombocytopenia> 600 × 10 ~ 9 / L for the human standard, a prospective non-randomized study. Began to subcutaneous daily subcutaneous interferon 3 × 10 ~ 6U, no response to treatment in the 2-4 weeks period increased to 4.5,9 and 18 × 10 ~ 6U, platelet count normalized, and gradually reduced to maintain platelet count at Normal level, such as the occurrence of vice